Medication leaflets

Active substance

Results for the substance denosumab

19 results

About this active substance

Denosumab is a monoclonal antibody used to treat bone-related conditions associated with loss of bone density. It is primarily indicated for osteoporosis in postmenopausal women and men at high risk of fractures, as well as for preventing skeletal complications in patients with bone metastases from solid tumors. It is also used in the treatment of cancer-related hypercalcemia and other conditions involving excessive bone resorption.

Denosumab works by inhibiting RANKL (receptor activator of nuclear factor kappa-B ligand), a protein that stimulates osteoclast activity, the cells responsible for bone resorption. By blocking RANKL, denosumab reduces bone loss, increases bone mineral density, and lowers the risk of fractures.

It is administered as a subcutaneous injection, typically once every 6 months for osteoporosis or more frequently for other indications. Common side effects include muscle or joint pain, upper respiratory tract infections, and injection site reactions. Rarely, it may cause hypocalcemia, osteonecrosis of the jaw, or atypical fractures.

Patients should strictly follow their doctor’s recommendations, maintain adequate calcium and vitamin D intake, and report any side effects or other medications they are taking.